ArticleThe Journal of veterinary medical science2020
Biomarkers for chronic kidney disease in dogs: a comparison study.
Article in The Journal of veterinary medical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 17 citations in OpenAlex.
- Supplementation withThe veterinary quarterly · 2026Article
- Evaluation of Urinary Tubular Biomarkers in Dogs with Myxomatous Mitral Valve Disease Across ACVIM Stages.Veterinary sciences · 2026Article
- Article
- A pilot study investigating renal biomarkers in dogs with pulmonary hypertension: a comparison between cystatin-C, symmetric dimethylarginine, and creatinine.The Journal of veterinary medical science · 2025Article
- Urinary Gamma-Glutamil Transferase as an Early Biomarker of Renal Disease in Dogs with Leishmaniosis.Veterinary sciences · 2025Article
- Real-world data on canine chronic kidney disease in Greece: clinical and quality of life insights.Frontiers in veterinary science · 2025Article
- Diagnostic validation of the urine albumin-to-creatinine ratio for early renal disease in healthy dogs and dogs with chronic kidney disease.Journal of veterinary science · 2024Article
- Cystatin C assay validation using the immunoturbidimetric method to evaluate the renal function of healthy dogs and dogs with acute renal injury.Veterinary world · 2022Article
- A Review of Specific Biomarkers of Chronic Renal Injury and Their Potential Application in Nonclinical Safety Assessment Studies.Toxicologic pathology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine whether serum symmetric dimethylarginine (SDMA) and cystatin C (CysC) levels can be utilized as more accurate markers of early kidney dysfunction in dogs. Forty-one client-owned dogs with chronic kidney disease (CKD), which were clinically stable, and ten beagles as healthy controls were included. All dogs underwent physical examination, systemic blood pressure measurement, complete blood cell count, and plasma biochemistry analyses. Frozen serum was used for SDMA and CysC analyses. Data analysis was performed using Kruskal Wallis, Pearson's correlation, Bland-Altman plots, and receiver operating characteristic curve. SDMA and CysC levels were significantly higher in patients with CKD at various International Renal Interest Society (IRIS) stages than in the healthy controls. In particular, CysC level was the only biomarker that could indicate the earliest stage of CKD (IRIS stage I). Similar to these results, CysC level showed better sensitivity and specificity compared to the other biomarkers in early CKD dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.